证券代码：300832 证券简称：新产业 公告编号：2025-003 一、 股东减持股份情况 深圳市新产业生物医学工程股份有限公司 关于持股 5%以上股东持股变动比例达到 1% 暨减持计划实施完成的公告 持股 5%以上的股东天津红杉聚业股权投资合伙企业（有限合伙）保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证本公告内容与信息披露义务人提供的信息一 致。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于 2024 年 11 月 8 日披露了《关于持股 5%以上股东股份减持计划的预披露公告》（公告编号： 2024-091，以下简称"减持计划"）。公司持股 5%以上的股东天津红杉聚业股权 投资合伙企业（有限合伙）（以下简称"红杉聚业"）计划通过大宗交易方式减 持公司股份的数量不超过公司总股本的 1%（对应的公司股份数量为不超过 7,857,187 股）。若公司在本减持计划实施期间发生送股、资本公积转增股本、配 股等变动事项，减持数量进行相应调整。 公司于近日收到红杉聚业出具的《关于新产业股份减持计划实施完毕的告知 函》《关于新产业股份权益变动 ...

此次开工、竣工的新项目投资规模大、科技含量高、市场前景好，将为苏州产业集群发展提供有力支 撑。 证券时报记者 臧晓松 1月2日，新年第一个工作日，亨通集团项目开竣工仪式在苏州吴江举行。 "亨通紧跟全球能源绿色转型时代浪潮，聚焦电力能源产业发展不断强链补链延链，持续打造具有行业 引领力和全球竞争力的绿色电力能源创新产业集群。"亨通集团总裁崔巍说。 崔巍表示，亨通将充分发挥产业集群优势，以先进制造融合科技创新，以科技创新驱动产业升级，不断 向产业链价值链高端迈进，为地方经济社会高质量发展贡献力量。 亨通集团相关人士向证券时报记者表示，此次开工、竣工的四个项目涉及新一代通信技术、工业连接、 风光储新能源等领域及配套智能物流平台，将大大提升亨通光电科技产业园创新集群竞争力，建设成为 具有全球竞争力的世界一流产业园区。 近日，由亨通集团参建的全国规模最大的光氢储一体化海上光伏示范项目成功并网发电。该项目地处江 苏省如东县豫东垦区堤外滩涂，是国内首个滩涂生态治理光伏项目，项目将先进光伏技术与智能化控制 系统巧妙结合，实现能量转换与储存的高效运行。项目建成投产后，年平均上网电量约4.6亿千瓦时， 相当于节约标煤15.1万吨 ...

Group 1: Energy Transition and Industry Upgrading - The coal industry is a traditional pillar for Changzhi, with 22 green mining operations and 17 intelligent mines established, achieving advanced production capacities of 93% and 94% respectively [1] - Changzhi is transitioning from an energy city to an energy stronghold, combining traditional and new clean energy sources [2] - The city has seen significant growth in high-tech manufacturing, with a 31% increase in high-tech equipment manufacturing value added, and 12.6% and 12.4% growth in automotive and pharmaceutical industries respectively [5] Group 2: Digital Economy and Technological Innovation - Changzhi has focused on digital economy development, establishing a digital economy association and becoming a pilot city for small and medium-sized enterprise digital transformation, with a core industry output value of 10.2 billion yuan in the first three quarters [3] - The city is nurturing a cluster of innovation-driven enterprises in computing, software, and artificial intelligence, led by Longxin Zhongke [3] - The company Shanxi High-Tech Huaye Electronics has achieved a 70% automation level in its production processes, significantly reducing production time and heat generation [2][7] Group 3: Talent Development and Support - Changzhi has implemented a talent-oriented strategy, creating a city-level talent group and service alliance to attract and support skilled professionals [9] - The city has established a digital service platform to enhance talent services, promoting Changzhi as a desirable location for living and working [9] - Significant investments in technology innovation have been made, with individual project subsidies reaching up to 10 million yuan, fostering collaboration with over 150 universities [10]

证券代码：300832 证券简称：新产业 公告编号：2024-096 深圳市新产业生物医学工程股份有限公司 关于审计机构变更签字注册会计师及项目质量复核人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 项目签字注册会计师：陈礼珍，2020 年 4 月成为注册会计师，2016 年 6 月 开始从事上市公司和挂牌公司审计工作，2024 年 11 月开始在政旦志远执业， 2024 年 12 月开始为本公司提供审计服务，近三年签署上市公司审计报告数量超 过 2 家次。 项目质量复核人：柯敏婵，2014 年 4 月成为注册会计师，2006 年 8 月开始 从事上市公司和挂牌公司审计工作，2023 年 9 月开始在政旦志远执业，2024 年 12 月开始为本公司提供审计服务，近三年签署或复核上市公司审计报告数量超 过 6 家次。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于 2024 年 4 月 11 日召开了第四届董事会第十三次会议，于 2024 年 5 月 6 日召开 2023 年 年度股东大会，审议通过了《关于续聘深圳大华国际会计师事务所为公司 ...

证券代码：300832 证券简称：新产业 公告编号：2024-095 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： | 产品名称 | 注册 分类 | 注册证编号 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 腺苷脱氨酶测定试 剂盒（过氧化物酶 法） | Ⅱ类 | 粤械注准 20242401663 | 2024 2029 | 年 | 12 | 月 10 | 日至 | 本试剂用于体外定量测 定人血清、血浆、胸水和 （ADA）的活性。临床上 | | | | | | | | | | 腹 水 中 腺 苷 脱 氨 酶 | | | | | | 年 | 12 | 月 09 | 日 | | | | | | | | | | | 用于辅助评价肝损伤和 | ...

证券代码：300832 证券简称：新产业 公告编号：2024-094 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 2 项《医疗器械注册证》。具体情况如下： | 序 号 | 产品名称 | 注册 分类 | 注册证编号 | | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 亮氨酸氨基肽酶测 定试剂盒（L-亮氨 酰-p-硝基苯胺底 | Ⅱ类 | 粤械注准 20242401602 | 2024 2029 | 年 年 | 11 11 | 月 月 | 29 28 | 日至 日 | 本试剂盒用于体外定量 测定人血清或血浆中亮 氨酸氨基肽酶的活性。临 | | | 物法） | | | | | | | | | 床上主要用于肝、胆疾病 的辅助诊断。 | | 2 | 钙测 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [1][2][164]. Core Insights - The company is a leading player in the chemical luminescence in vitro diagnostics sector in China, benefiting from both domestic and international growth drivers [1][14]. - High-margin reagents are the primary source of profit for the company, with the X8 series instruments contributing significantly to testing volume [1][2]. - The domestic market for in-hospital testing is increasingly concentrated in tertiary hospitals, which are expected to capture a larger share of the domestic replacement market [1][2][32]. Summary by Sections Company Overview - The company, established in 1995, specializes in the research, production, and sales of automated chemical luminescence immunoassay instruments and reagents, holding a market share of 5.2% in 2021 [1][14]. - As of H1 2024, the company has achieved a coverage rate of 60.2% in domestic tertiary hospitals and serves medical terminals in 155 countries and regions [1][14]. Market Dynamics - The in vitro diagnostics (IVD) industry in China is experiencing a shift towards tertiary hospitals, which are expected to account for approximately 70% of the in-hospital testing market by 2023 [1][24][32]. - The chemical luminescence market in China has a low domestic replacement rate of about 30%, indicating significant growth potential as domestic companies increase their market share [1][76]. Financial Projections - Revenue projections for the company are estimated at CNY 46.2 billion, CNY 55.3 billion, and CNY 66.0 billion for 2024E, 2025E, and 2026E respectively, with a compound annual growth rate (CAGR) of 19.5% for net profit [2][164]. - The company’s net profit is projected to reach CNY 19.2 billion, CNY 23.2 billion, and CNY 28.1 billion over the same period [2][164]. Competitive Position - The company has a strong competitive position in the high-end market, with the X8 and T8 series instruments expected to capture significant market share in domestic replacements [1][14][32]. - The introduction of the SATLARS T8 automated sample processing system is anticipated to enhance the company's competitiveness in tertiary hospitals [1][123]. Valuation - The company's current PE-TTM is 29.21, indicating a stable valuation level that is considered low, with potential for upward movement as the market stabilizes [2][166].

Core Viewpoint - The approval of China Communications Construction Company's issuance of technology innovation perpetual bonds marks the first issuance of such bonds by a central enterprise on the Sci-Tech Innovation Board, indicating a significant step in enhancing financing channels for technology innovation companies [1] Group 1: Growth of Sci-Tech Bonds - Since the comprehensive launch of Sci-Tech bonds in May 2022, the issuance quantity and scale have been rapidly increasing, with 1,111 bonds issued in 2023, totaling approximately 1.12 trillion yuan, representing growth rates of 41.35% and 45.01% respectively compared to the previous year [2][3] - The issuance period of Sci-Tech bonds has lengthened significantly, with 410 bonds (36.90% of total) having a maturity of five years or more, accounting for 39.17% of the total issuance scale [2] Group 2: Factors Driving Issuance - Multiple factors contribute to the continuous increase in Sci-Tech bond issuance, including supportive policies, optimized issuance conditions, and changing investor preferences [3] - Regulatory measures such as the "green channel" have improved issuance efficiency, while abundant market liquidity and declining interest rates have reduced financing costs for enterprises [3] - The current low-interest environment has encouraged enterprises to issue bonds, with the high-quality credentials of Sci-Tech bond issuers attracting investor interest [3] Group 3: Support for Technology Innovation - The rapid development of the Sci-Tech bond market provides more financing channels for technology innovation companies and opportunities for traditional enterprises to upgrade [4] - The primary sectors for bond issuance include construction, manufacturing, mining, public utilities, and transportation, with significant issuance scales in these industries [4] Group 4: Use of Proceeds - The funds raised through Sci-Tech bonds are primarily used for repaying existing debts, supplementing working capital, equity investments, and technology innovation project construction [5][6] - The unique use of funds for equity investments in technology innovation projects is gaining popularity among issuers, indicating a shift towards supporting early-stage and growth-stage technology companies [5] Group 5: Economic Impact - The targeted use of funds for technology innovation enhances enterprises' capabilities, promotes the transformation of technological achievements, and drives industrial upgrades and economic development [7] - There is a need to lower the issuance threshold for small and medium-sized private technology enterprises, as they often struggle to obtain high ratings, which limits their access to the Sci-Tech bond market [7] - The continued growth of Sci-Tech bond issuance is expected to attract more social funds into the technology innovation sector, thereby enhancing economic vitality and promoting high-quality economic development [7]

Group 1: Event Overview - The investor relations activity involved 32 institutions with a total of 63 participants [1] - The event took place from November 4 to November 29, 2024, at the New Industry Biomedical Building, Shenzhen [1] - The main attendees included the Chairman and General Manager, Rao Wei, and the Deputy General Manager and Secretary of the Board, Zhang Lei, along with Lu Yuning [1] Group 2: Activity Types - The types of activities included on-site visits, analyst meetings, media interviews, performance briefings, news releases, and roadshows [1] - Other activities mentioned were strategy meetings with various financial institutions [1] Group 3: Content of the Meeting - The main content of the investor relations activity did not include any new major communication beyond previously disclosed information [1]

证券代码：300832 证券简称：新产业 公告编号：2024-093 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： | 产品名称 | 注册 分类 | 注册证编号 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 补体 C3 测定试剂 盒（免疫透射比浊 | Ⅱ类 | 粤械注准 | 2024 | 年 | 11 月 | 21 | 日至 | 本试剂盒用于体外定量 测定人血清和血浆中补 体 C3（C3）的含量。临 | | 法） | | 20242401551 | 2029 | 年 | 月 11 | 日 20 | | 床上用于补体低下或相 | | | | | | | | | | 关免疫缺陷性疾病的辅 | | | | | | | | | | 助诊断。 ...